Fig. 6

GPMQN therapy assay of HepG2/ADM cells treated with GPMQNs. A Inhibition of tumor growth in HepG2/ADM nude mice with different treatments, a untreated used as control, b treated 10 mg kg⁻¹ GPMQNs without loading miR-122, c transfected with miR-122 (1 mg kg⁻¹, same concentration as loaded on GPMQNs), d treated 10 mg kg⁻¹ GPMQNs. B HE staining was performed on tissue sections of HepG2/ADM xenograft tumors treated as follows: a untreated used as control, b treated 10 mg kg⁻¹ GPMQNs without loading miR-122, c transfected with miR-122 (1 mg kg⁻¹, same concentration as loaded on GPMQNs), d treated 10 mg kg⁻¹ GPMQNs. C The effect of different treatments on the tumor growth inhibition in HepG2/ADM nude mice. a untreated used as control, b treated 10 mg kg⁻¹ GPMQNs without loading miR-122, c transfected with miR-122 (1 mg kg⁻¹, same concentration as loaded on GPMQNs), d treated 10 mg L⁻¹ GPMQNs. D Distribution of indium levels in various tissues from different treatment groups. The HepG2/ADM nude mice were treated the same way as shown in (C). 1 Brain, 2 Muscle, 3 Skin, 4 Liver, 5 Intestine, 6 Tumor. (*P < 0.05 compared to the control group)